Amantadine
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.90 | $54.00 (0%) | 🛒 Add to cart |
| 90 | $0.82 | $81.00 $74.00 (9%) | 🛒 Add to cart |
| 120 | $0.78 | $108.00 $94.00 (13%) | 🛒 Add to cart |
| 180 | $0.73 | $162.00 $132.00 (19%) | 🛒 Add to cart |
| 270 | $0.71 | $243.00 $193.00 (21%) | 🛒 Add to cart |
| 360 | $0.69
Best per pill | $324.00 $249.00 (23%) | 🛒 Add to cart |
Synonyms | |||
More info:
Bupropion SR: Effective Relief for Major Depressive Disorder
Bupropion SR (sustained-release) is a widely prescribed antidepressant belonging to the aminoketone class, distinct from SSRIs and SNRIs. It functions primarily as a norepinephrine–dopamine reuptake inhibitor (NDRI), offering a unique mechanism of action for managing major depressive disorder. This formulation provides steady plasma concentrations over 12 hours, supporting consistent therapeutic effect with twice-daily dosing. Clinicians often favor bupropion SR for its favorable side effect profile, particularly the low incidence of sexual dysfunction and weight gain associated with other antidepressants.
Bupropion: A Leading Antidepressant for Depression and Smoking Cessation
Bupropion is a widely prescribed antidepressant medication belonging to the class of norepinephrine-dopamine reuptake inhibitors (NDRIs). It is primarily indicated for the treatment of major depressive disorder (MDD) and to aid in smoking cessation. Unlike many other antidepressants, bupropion does not significantly affect serotonin levels, which contributes to its distinct side effect profile and makes it a favorable option for patients who cannot tolerate serotonergic agents. Its dual mechanism of action enhances norepinephrine and dopamine neurotransmission, which is associated with improvements in mood, energy, and motivation.
Wellbutrin SR: Sustained Relief for Major Depressive Disorder
Wellbutrin SR (bupropion hydrochloride) is a second-generation antidepressant and aminoketone-class medication specifically formulated with sustained-release technology. This formulation provides stable plasma concentrations over a 12-hour dosing interval, offering clinicians a valuable therapeutic option with a distinctive neuropharmacological profile. Unlike many serotonin-based antidepressants, Wellbutrin SR primarily acts as a norepinephrine-dopamine reuptake inhibitor (NDRI), making it particularly suitable for patients who experience undesirable effects with other antidepressant classes or require alternative mechanisms of action.
Wellbutrin: Effective Relief for Major Depressive Disorder
Wellbutrin (bupropion hydrochloride) is a prescription antidepressant medication belonging to the aminoketone class, distinct from commonly prescribed selective serotonin reuptake inhibitors (SSRIs). It is primarily indicated for the treatment of major depressive disorder (MDD) and is also approved for the prevention of seasonal affective disorder (SAD) and as an aid to smoking cessation. Its unique neurochemical profile, primarily acting as a norepinephrine–dopamine reuptake inhibitor (NDRI), offers a valuable therapeutic alternative, particularly for patients who experience undesirable side effects like sexual dysfunction or weight gain with other antidepressant classes.
Zyban: A Clinically Proven Aid for Smoking Cessation
Zyban (bupropion hydrochloride) is a prescription medication specifically developed to support adults in their journey to quit smoking. Unlike nicotine replacement therapies, Zyban works by affecting neurotransmitters in the brain associated with nicotine addiction and withdrawal. It is designed to reduce the urge to smoke and alleviate withdrawal symptoms, providing a non-nicotine pharmacological approach to smoking cessation. Clinical studies have demonstrated its efficacy when used as part of a comprehensive cessation program that includes behavioral support and counseling.
Abilify: Advanced Antipsychotic for Symptom Control and Stability
Abilify (aripiprazole) is an atypical antipsychotic medication engineered to provide a sophisticated mechanism of action for managing complex psychiatric conditions. It functions as a partial agonist, offering a unique modulatory effect on dopamine and serotonin receptors, which contributes to its efficacy and generally favorable tolerability profile. This medication is a cornerstone in the long-term management of schizophrenia, bipolar disorder, and as an adjunct in major depressive disorder, providing patients with a path toward sustained symptom control and improved functional outcomes.
Amitriptyline: Effective Relief for Chronic Pain and Depression
Amitriptyline is a tricyclic antidepressant (TCA) with a well-established profile for managing major depressive disorder and a range of chronic pain conditions. Its dual-action mechanism modulates serotonin and norepinephrine reuptake, offering both mood stabilization and central pain modulation. It is particularly valued in clinical practice for its efficacy in neuropathic pain, migraine prophylaxis, and as a second-line option for depression when SSRIs are ineffective or poorly tolerated. This product card provides a comprehensive, evidence-based overview for healthcare professionals.
Anafranil: Restoring Balance in Severe OCD Treatment
Anafranil (clomipramine hydrochloride) is a tricyclic antidepressant (TCA) with potent serotonin reuptake inhibition properties, specifically approved for the treatment of obsessive-compulsive disorder (OCD). It represents a foundational pharmacological intervention for moderate to severe OCD cases where first-line treatments prove insufficient. Its efficacy is well-documented in clinical literature, offering a robust option for patients struggling with intrusive thoughts and compulsive behaviors. By modulating key neurotransmitter systems, it helps reduce the core symptoms that significantly impair daily functioning and quality of life.
Asendin: Targeted Relief for Endogenous Depression with Dual-Action Efficacy
Asendin (amoxapine) is a tetracyclic antidepressant (TeCA) medication indicated for the relief of symptoms of endogenous depression. It represents a distinct class of agent that combines potent norepinephrine reuptake inhibition with secondary dopamine receptor blockade, offering a unique neurochemical profile for cases where first-line selective serotonin reuptake inhibitors (SSRIs) prove inadequate or intolerable. Its mechanism provides a rapid onset of action for certain symptoms, particularly psychomotor retardation, often within the first week of treatment.